Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena Wolff-Holz

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|October 9, 2020
[Biosimilars in the European Union: current situation and challenges]Elena Wolff-Holz, Martina Weise
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 22, 2019
Evolution of the EU Biosimilar Framework: Past and FutureElena Wolff-Holz, Klara Tiitso, Camille Vleminckx, et al.
Clinical Pharmacology and Therapeutics|December 22, 2022
A Data Driven Approach to Support Tailored Clinical Programs for Biosimilar Monoclonal AntibodiesElena Guillen, Niklas Ekman, Sean Barry, et al.
Drugs|October 1, 2021
Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory PerspectivePekka Kurki, Sean Barry, Ingrid Bourges, et al.
Blood|October 10, 2014
Biosimilars: the science of extrapolationMartina Weise, Pekka Kurki, Elena Wolff-Holz, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 26, 2017
Interchangeability of Biosimilars: A European PerspectivePekka Kurki, Leon van Aerts, Elena Wolff-Holz, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 21, 2022
Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical ExperiencePekka Kurki, Hye-Na Kang, Niklas Ekman, et al.
Clinical Pharmacology and Therapeutics|November 22, 2018
Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical PracticeNiels S Vermeer, Thijs J Giezen, Sofia Zastavnik, et al.
Clinical Pharmacology and Therapeutics|September 2, 2021
Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug ReactionsLuis Correia Pinheiro, Thijs J Giezen, Elena Wolff-Holz, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 17, 2025
Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case StudyMartin Schiestl, Nivedita Roy, Michael Trieb, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|October 9, 2020
[Biosimilars in the European Union: current situation and challenges]Elena Wolff-Holz, Martina Weise
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 22, 2019
Evolution of the EU Biosimilar Framework: Past and FutureElena Wolff-Holz, Klara Tiitso, Camille Vleminckx, et al.
Clinical Pharmacology and Therapeutics|December 22, 2022
A Data Driven Approach to Support Tailored Clinical Programs for Biosimilar Monoclonal AntibodiesElena Guillen, Niklas Ekman, Sean Barry, et al.
Drugs|October 1, 2021
Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory PerspectivePekka Kurki, Sean Barry, Ingrid Bourges, et al.
Blood|October 10, 2014
Biosimilars: the science of extrapolationMartina Weise, Pekka Kurki, Elena Wolff-Holz, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 26, 2017
Interchangeability of Biosimilars: A European PerspectivePekka Kurki, Leon van Aerts, Elena Wolff-Holz, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 21, 2022
Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical ExperiencePekka Kurki, Hye-Na Kang, Niklas Ekman, et al.
Clinical Pharmacology and Therapeutics|November 22, 2018
Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical PracticeNiels S Vermeer, Thijs J Giezen, Sofia Zastavnik, et al.
Clinical Pharmacology and Therapeutics|September 2, 2021
Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug ReactionsLuis Correia Pinheiro, Thijs J Giezen, Elena Wolff-Holz, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 17, 2025
Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case StudyMartin Schiestl, Nivedita Roy, Michael Trieb, et al.
Pageof 2